Annovis Bio logo
Annovis Bio
ANVS | NYSE
Chart Builder DCF Calculator
$0.76
-$0.17 (-17.94%)
At close: Nov 16, 2026, 3:59 PM ET
$0.78
+$0.02 (+2.63%)
After-hours: Nov 16, 2026, 7:36 PM ET

Annovis Bio Company Profile

Company profile explained

Company Profile

Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.

Key Executives

Name Position
Maria L. Maccecchini Founder, Acting CFO, CEO, President & Executive Director
Blake Jensen Head of Quality
Cheng Fang Chief Scientific Officer
Eve Damiano Senior Vice President of Regulatory Operations
Hilda Maibach Senior Vice President of Statistics

Latest SEC Filings

Date Type Title
Oct 30, 2026 8-K Current Report
Oct 20, 2026 8-K Current Report
Oct 15, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Oct 07, 2026 DEFA14A Filing
Sep 11, 2026 DEF 14A Filing
Aug 25, 2026 PRE 14A Filing
Aug 14, 2026 10-Q Quarterly Report
Aug 14, 2026 8-K Current Report
Aug 14, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Jul 29, 2026 SC 13G Statement of acquisition of beneficial ownership b...
View All SEC Filings ➞
Annovis Bio
Annovis Bio logo
Country United States
IPO Date Jan 29, 2020
Industry Biotechnology
Sector Healthcare
Employees 7
CEO Maria L. Maccecchini

Contact Details

101 Lindenwood Drive Malvern, Pennsylvania 19355 United States

Stock Details

Ticker Symbol ANVS
Exchange NYSE
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001477845
CUSIP Number 03615A108
ISIN Number US03615A1088
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.